Holds 2 active US DMFs and 2 valid CEPs for sorafenib, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one active US DMF for sorafenib, filing since 2016. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds 2 active US DMFs and 4 valid CEPs for sorafenib, filing since 2019. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 2 active US DMFs and 2 valid CEPs for sorafenib, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 7 markets.
Holds one active US DMF for sorafenib, filing since 2014. Its 2022 FDA inspection closed as NAI, and its GMP is recognised in 13 markets.
Holds 3 active US DMFs for sorafenib, filing since 2016. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds 2 active US DMFs for sorafenib, filing since 2012. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Holds one valid CEP for sorafenib, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for sorafenib, filing since 2022. Its 2025 FDA inspection closed as VAI.
This page filters the worldwide Sorafenib manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Ask Fred which manufacturers are on record for sorafenib and what filings they hold.
Chat with Fred, your AI analyst